A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II EFFICACY AND SAFETY STUDY OF THE PDE10A INHIBITOR PF-02545920 IN HUNTINGTON DISEASE (AMARYLLIS)

被引：11

作者：

Delnomdedieu, Marielle ^{[1
]}

Tan, Ye ^{[1
]}

Ogden, Adam ^{[2
]}

Berger, Zdenek ^{[1
]}

Reilmann, Ralf ^{[3
,4
,5
,6
,7
]}

机构：

[1] Pfizer Inc, Cambridge, MA USA

[2] Pfizer Early Clin Res, Groton, CT USA

[3] George Huntington Inst, Munster, Germany

[4] QuantiMedis GmbH, Munster, Germany

[5] Univ Munster, Dept Clin Radiol, Munster, Germany

[6] Univ Tubingen, Dept Neurodegenerat Dis, Tubingen, Germany

[7] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany

来源：

关键词：

D O I：

10.1136/jnnp-2018-EHDN.266

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

J06

引用

页码：A99 / A100

页数：2